Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HSBC Upgrades Koninklijke Philips to Buy

HSBC analyst Sezgi Oezener upgrades Koninklijke Philips (NYSE:PHG) from Hold to Buy.

byBenzinga Newsdesk

January 14, 2022

1 minute read

HSBC analyst Sezgi Oezener upgrades Koninklijke Philips (NYSE:PHG) from Hold to Buy.

HC Wainwright & Co. Downgrades Intrusion to Neutral, Lowers Price Target to $5

By Benzinga Newsdesk

Today, 8:58 PM

HC Wainwright & Co. analyst Scott Buck downgrades Intrusion (NASDAQ:INTZ) from Buy to Neutral and lowers the price target from $25 to $5.

INTZ

Tencent Terminates Exclusive Music Copyright Agreements Post Government Crackdown: Reuters

By Anusuya Lahiri

Today, 8:58 PM

Tencent Holdings Ltd (OTC:TCEHY) has ended all exclusive music copyright agreements after Chinese regulators barred it from such deals…

NTES

FDA
News

Blueprint Medicines’ Ayvakyt Receives European Commission Approval For The Treatment Of Adults With Advanced Systemic Mastocytosis

By Benzinga Newsdesk

Today, 8:58 PM

Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that the European Commission (EC) has expanded the current indication for AYVAKYT® (avapritinib) to include monotherapy for the treatment of adult

BPMC

Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $29

By Benzinga Newsdesk

Today, 8:58 PM

Morgan Stanley analyst Tejas Savant maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and lowers the price target from $32 to $29.

MRVI

HSBC Upgrades Koninklijke Philips to Buy

Related Posts

HC Wainwright & Co. Downgrades Intrusion to Neutral, Lowers Price Target to $5

Tencent Terminates Exclusive Music Copyright Agreements Post Government Crackdown: Reuters

Blueprint Medicines’ Ayvakyt Receives European Commission Approval For The Treatment Of Adults With Advanced Systemic Mastocytosis

Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $29